The ALS Ice Bucket Challenge was a tremendous event in our Association’s history, raising $115 million in the summer of 2014. Not only did it bring awareness to this devastating disease, it importantly spurred a huge increase in our research budget. Since the IBC, we have committed over $96.4 million toward our mission, including over $84 million in research projects.
The ALS Association is committed to transparency in how donor dollars are helping to fuel efforts to find treatments and a cure for the disease. Below, you will find links and dollar figures associated with all of the projects and initiatives announced by The ALS Association that we have committed to fund using money raised during the 2014 ALS Ice Bucket Challenge.
Along with receiving tremendous help from volunteers, we are committed to maximizing all donations from the Ice Bucket Challenge and beyond by partnering with other organizations to fund the most promising ALS research all over the world.
These figures will be updated periodically as new commitments are added in the future. For questions, please contact firstname.lastname@example.org.
For more information about our premier global research program, check out our research toolkit here.
Grants to Treatment Centers - $3,315,000
Community and Support Grants - $8,500,000
Grants in Clinical Care Management and Data Collection - $655,855 and $100,000
Grand Challenge to Develop a TDP43 Biomarker - $1 million
NeuroLINCS Program - $2.5 million
ALS ACT - $10,500,000
New York Genome Center - $2,500,000
Neurocollaborative - $5,000,000
Project Mine - $1,000,000
Clinical Management Grant - $50,000
Clinical Research Training Fellow - $86,667
Biomarker Discovery and Validation Projects - $1,199,841
2015 Annual Research Awards - $11,621,638
Amylyx Pharmaceuticals - $734,350
TREAT ALS™ NEALS Clinical Trial Network - $2,621,821
Expand NeuroBANK - $1,679,091
ALS Association 2016 Starter Grant Awards - $425,000
ALS ONE Massachusetts ALS Partnership (MAP) - $2 million
RNS60 Trial with Biomarkers - $500,000
Assistive Technology Challenge - $400,000
Additional Funding to Project MinE U.S. - $671,385
Biomarker Grand Challenge Award Winner - $499,966
2017 Sheila Essey Award winner - $50,000
2017 Clinical Research Fellowships - $370,000
ALS Online Genetics Database (ALSoD) Update - $150,000
Additional Funding to the Neuro Collaborative - $2,000,000
ALS Association 2017 Starter Grant Awards - $500,000
2017 Clinical Management Grants - $534,392
2017 Strategic Initiatives - $2,713,512
The ALS Association and its network of chapters currently partner with 58 ALS Association Certified Treatment Centers of Excellence across the United States. Multiple studies have shown the value to a person living with ALS of attending a multidisciplinary clinic, including longer survival, increased quality of life, and improved access to potential therapies. One of the requirements in achieving certification through The ALS Association is for the institution to be actively involved in ALS-related research and to provide information to people living with the disease on research outside of their institution. Participation in clinical trials is imperative to the research process to find treatments for the disease. ALS Ice Bucket Challenge donations have enabled the Association to increase the number of centers and the size of its annual grants to the centers from the previously budgeted $12,500 to $25,000 per center. The ALS Association was also able to begin providing $5,000 annual grants to a number of its Recognized Treatment Centers of Excellence.
The ALS Association has 39 chapters in communities across the country that are providing care and support to people living with ALS. The ALS Association gave $8.5 million in funding to chapters to augment local programs and services to people living with ALS. Chapters have been able to accomplish the following: restock and expand equipment loan closets; expand services into Idaho and Utah; launch a telemedicine program to help home-bound patients; and increase patient access to care. Other stories of how chapters are making a difference can be found here.
Organizations involved in two other neurological diseases (Alzheimer’s and Duchenne Muscular Dystrophy) have seen great benefits in working to develop guidance for companies to help them navigate the regulatory pathway for approval of effective therapies. As announced in the press release in October 2014, the enactment of the patient-focused drug development elements of the Food and Drug Administration Safety and Innovation Act (FDASIA) presents a unique opportunity for The ALS Association to help expedite drug development by developing similar guidance for ALS. No such guidance exists today for ALS, which creates uncertainty and risk for what is already a difficult and costly process. By developing this guidance, The ALS Association will be able to build on and strengthen its engagement with the FDA, industry and people with ALS about drug development as a regulatory process, which will reduce obstacles that can slow and limit innovation and access to effective treatments.
In August 2015, The ALS Association and Columbia University Medical Center (CUMC) announced a collaboration to better understand the differences and commonalities in the ALS disease process and how genes influence the clinical features of the disease. The project, “Genomic Translation for ALS Clinical care” (GTAC), involves a combination of next generation genetic sequencing and detailed clinical phenotyping in 1500 people with ALS. The goal of the project is to provide a basis for the development of precision medicine, or more individually tailored therapies for ALS
In September 2015, The ALS Association and Target ALS announced the launch of a new collaborative effort to expand the collection of biofluids from people with ALS, to be used for research to better understand the disease and ultimately develop new treatments. The ALS Association is investing $1,392,668 over 38 months. Funding from The ALS Association will allow pre-mortem biofluids (serum, plasma, and cerebrospinal fluid) to be collected and stored at the sites that comprise the Target ALS Postmortem Tissue Core at Barrow Neurological Institute/Saint Joseph’s Hospital in Phoenix, Columbia University in New York, Georgetown University in Washington D.C., Johns Hopkins University in Baltimore, and University of California at San Diego. Detailed genetic analysis will be performed on all these cases at The New York Genome Center, all the data will be linked, and all of the samples and data will be made available for researchers around the world.
The ALS Association is pleased to announce the launch of a new collaborative effort with TARGET ALS to perform whole genome sequencing from people who have died from ALS, to be used for research to better understand the disease and ultimately develop new treatments. Funding from The ALS Association and the Tow Foundation will be used by The New York Genome Center to determine the entire genetic sequence of people with ALS who have elected to donate their tissues after death to the Target ALS Postmortem Tissue Core at Barrow Neurological Institute/Saint Joseph’s Hospital in Phoenix, Columbia University in New York, Georgetown University in Washington D.C., Johns Hopkins University in Baltimore and University of California at San Diego.
In September 2015, The ALS Association and the CReATe Consortium announced the selection for funding of two new projects that will advance the discovery and validation of biomarkers relevant to ALS therapy development.
In October 2015, The ALS Association, in partnership with Prize4Life, announced The ALS Assistive Technology Challenge to revolutionize communication technology solutions for people living with ALS.
In December 2015, The ALS Association awarded $1.3 million in ALS Association-Initiated grants, Investigator-Initiated grants, and Milton Safenowitz Postdoctoral Fellowships grants.
In January 2016, The ALS Association announced a new collaboration between the Gladstone Institutes in San Francisco, which is a member of The Association-funded Neuro Collaborative and the biotechnology company Biogen in Cambridge, Mass., to discover novel drug targets for the treatment of amyotrophic lateral sclerosis (ALS).
In February 2016, The ALS Association announced its support for four new clinical management grants that will address the gaps in amyotrophic lateral sclerosis (ALS) clinical care whose funding collectively totals to $655,855; and one new ALS Association-Initiated grant awardee whose project is to streamline data collection at ALS clinics for funding of $100,000.
In February 2016, The ALS Association, in partnership with ALS Finding a Cure, announced the Grand Challenge to generate a biomarker to track TDP43 aggregation. The successful team(s) with the most developed plan will receive up to a $1 million investment.
In February 2016, The ALS Association announced the Translational Research Advancing Therapy for ALS (TREAT ALS™) Drug Development Contract grant program to fund milestone-driven research to develop new treatments for ALS. This program supports research from early target identification to preclinical research and early pilot clinical trials. The successful grants with the most developed plan will receive up to a $500,000 investment over a maximum two-year period.
In March 2016, The ALS Association announced five new Translational Research Advancing Therapy for ALS (TREAT ALS™) grant recipients to fund milestone driven research. These awards include a TREAT ALS™ Drug Development Contract grant and ALS Association-Initiated grants.
The ALS Association announced the awarding of an ALS Association-Initiated Grant to David Ennist, Ph.D., M.B.A, Chief Scientific Officer of Origent Data Sciences, Inc. based in Vienna, Virginia, for $497,433 over 34 months that will enable a research partnership with Cytokinetics Inc. (Nasdaq: CYTK) to improve clinical trial design. This collaboration will refine and prospectively validate an Origent computer model to predict the course of ALS disease progression leveraging data from Cytokinetics’ clinical trials of tirasemtiv, the first of its kind in a clinical trial setting.
In April 2016, The Association and the American Academy of Neurology (AAN) awarded Professor Ammar Al-Chalabi with the 2016 Sheila Essey Award at the American Academy of Neurology’s 68th Annual Meeting in Vancouver, Canada.
In June 2016, miRagen Therapeutics, Inc., a clinical-stage biopharmaceutical company developing innovative microRNA-based therapeutics and The ALS Association announced that miRagen has received the first installment of a Translational Research Advancing Therapy for ALS (TREAT ALS™) grant to advance the development of MRG-107, a synthetic microRNA antagonist (LNA antimiR®) of microRNA-155 that is effective in pre-clinical models of amyotrophic lateral sclerosis (ALS).
The ALS Association is pleased to work in partnership with the NIH’s National Institute of Neurological Disorders and Stroke (NINDS) to support NeuroLINCS, a collaborative effort among multiple research groups with expertise in induced pluripotent stem cell (iPSC) technology, disease modeling, OMICs and computational biology that is focused on gaining a deeper understanding of neurons and the causes of neurological diseases. The ALS Association contribution to NeuroLINCS is a $2.5 million commitment in partnership with the Greater Philadelphia Chapter over a five-year period to extend the current activities NeuroLINCS, which is one of six National Institute of Health (NIH) Library of Integrated Network-based Cellular Signature (LINCS) centers.
In October 2014, The ALS Association committed a total of $10 million to ALS ACT, a novel academic-foundation-industry partnership to accelerate treatments for people living with ALS. (The Association put in an additional $500,000 after this initial commitment was made in order to fund one additional clinical trial.) In partnership with the recently formed The ALS Finding a Cure Team, composed of researchers from General Electric (GE) Healthcare and four academic Northeast ALS Consortium (NEALS) sites, ALS ACT will enact a multi-pronged approach to expediting clinical trials in ALS. The ALS Association’s funds are being matched by The ALS Finding a Cure Foundation, for a total of $20 million. The projects below have been peer reviewed and approved, and represent commitments from both organizations:
Alex Sherman, Merit Cudkowicz, M.D., Massachusetts General Hospital, $650,000
NeuroBANK as an Accelerated Clinical Research Environment: Development, Deployment and Services to ALS Research Community
Successful implementation of NeuroBANK™ will allow for a standardized patient-centric approach to clinical research in ALS with information linked across studies, locations and modalities. Standard Common Data Elements, standard operating procedures and GUID technology will lead to accelerated studies' review, approval, deployment and patient enrollment
Clive Svendsen, Ph.D., Cedars-Sinai, $1,913,025
Inflammatory Biomarkers, Stem Cells and DNA in people with ALS
The goal of this project is to identify biomarkers of ALS that will gives us clues to disease mechanisms and help us identify targets for ALS therapy development. Specifically, we are planning to collect blood samples and skin biopsies from 50 people with ALS and 50 healthy volunteers. We will then use the blood samples to identify inflammatory markers of ALS and perform detailed DNA analysis. The skin biopsies will be used to generate stem cells from people with ALS and compare them to the stem cells from healthy volunteers. At the end of this project, we will identify inflammatory signatures of ALS and new targets and tools for drug development.
Clive Svendsen, Ph.D., Cedars-Sinai (in partnership with General Electric), $268,384
Application of MultiOmyx to iPSC Models of ALS
Induced pluripotent stem cell technology (iPSC) holds great promise for accelerating our understanding of the molecular mechanisms and pathways leading to motor neuron degeneration in ALS. In vitro cellular model systems generated from patient-derived iPSC lines can recapitulate many aspects of in vivo cellular pathology, and beyond basic disease research may serve as a powerful test bed to screen potential therapies. Therapeutic screening on iPSC-derived models will likely be complimentary to, and in some aspects superior to, other approaches including animal models in terms of human-predictivity and speed.
GE has developed a unique technology platform allowing the in vitro analysis of cells and tissues to an extent not previously possible (MultiOmyx, or “MO”). An iterative labeling process allows repeated immunocytochemical visualization of 60 or more protein markers in a single sample, as well as RNA and DNA. Precision hardware and custom software for imaging and analytics enables extensive characterization of single cell structure and function as well as relationships with neighboring cells and environment. Application of this technology to ALS iPSC systems is likely to advance the utility of these models and provide new insights into neurodegenerative pathways and mechanisms.
Clive Svendsen, Ph.D., Cedars-Sinai (in partnership with General Electric), $389,643
Using Novel Imaging Agents as a Biomarker for ALS
Assessing the progression of ALS in both animal models and the human condition would provide the ideal biomarker for testing novel compounds rapidly and efficiently. However, while MRI and other imaging modalities exist they have not been fine tuned for this neurological condition. Our rational is that through better imaging of disease progression in ALS within individual patients, drug therapy throughput and success will be increased.
We have just completed an extensive study mapping the exact progression of disease in the G93A rat model of familial ALS (fALS). Remarkably, this animal model of ALS reproduces many aspects of the disease including stochastic loss of motor neurons that could start in either cervical (20%) or lumbar (80%) regions of the spinal cord - mirroring the situation in patients.
GE Global Research has developed a novel superparamagnetic iron oxide (SPIO) nanoparticle for MR imaging of neuroinflammation. The agent was shown to be efficacious in brain and spinal cord imaging of acute neuroinflammation in an experimental autoimmune encephalomyelitis (EAE) model in the rat, with MR signal correlated with macrophages present within the CNS.
James Berry, M.D., Massachusetts General Hospital, $1,000,000
Infrastructure Improvement and Biofluid Collection Protocols for the Expansion of the NEALS Biorepository
The exact cause of amyotrophic lateral sclerosis remains unknown, and there are no tests to diagnose the disease or follow its progression. Such tests, known as biomarkers, would be invaluable to speed the development of novel therapies for ALS. In recent years, ALS scientists have begun to identify promising potential biomarkers in the blood and spinal fluid of people with the disease. The next step to build on these discoveries, in many cases, is to test larger numbers of biofluid samples to confirm the findings.
The Northeast ALS Consortium (NEALS) biorepository is a collection of biological samples, including blood and spinal fluid obtained from people with ALS that was created to be a resource for scientists conducting research in ALS. This project will allow us to upgrade the NEALS biorepository infrastructure, including updating the computer systems, expanding the number of sample freezers, and revising the standard operating procedures for the repository. The project also supports two efforts to expand the biorepository by collecting new blood and spinal fluid samples from people with ALS. This will ensure the NEALS biorepository remains a vital resource to the ALS scientific community.
Robert Brown, University of Massachusetts, $2,500,000
Development of AAV-Mediated SOD1 Gene Silencing Therapy in ALS
About 10 percent of ALS cases are familial. Most of the known genetic defects in familial ALS act by triggering one or more toxic processes that impair the viability of motor neurons, leading to motor neuron death. This project will use viruses to introduce reagents into the brain and spinal cord that block the mutant genes from triggering toxicity. This is accomplished by turning off the activity of those genes using new technologies for so-called “gene silencing.” The viruses are used to penetrate the blood-brain barrier to deliver the gene silencing reagents, which then inactivate the genes in question. This technology will be tested first in cases of ALS arising from mutations in well-defined ALS genes (e.g. SOD1 and C9orf72). This project is intended to take the gene silencing all the way to a pilot human trial. We are hopeful that in the long term these studies will lead to a general platform or method for treating other types of familial ALS and potentially also some cases of non-familial ALS.
Nazem Atassi, M.D., Massachusetts General Hospital (in partnership with General Electric), $3,929,181
This is collaborative project between industry, academia, the Leandro P Rizzuto (ALS Finding a Cure (ALSFAC)) Foundation and The ALS Association. The overall goal of this project is to identify imaging markers of ALS that can be used to accelerate ALS diagnostic timelines and the pace of ALS drug discovery. This project will focus on studying the role of brain inflammation in people with ALS.
In this project we plan to use innovative MRI and positron emission tomography (PET) tracer (contrast) that will show us the location and degree of nerve damage and brain inflammation in people with ALS. We plan to compare MRI signals between 50 people with ALS and 50 healthy volunteers and to study these MRI signals over time in relationship with ALS clinical presentation and disease progression. In a subgroup of patients, we plan to compare brain inflammation between 20 people with ALS and 20 healthy volunteers and to study brain inflammation over time in relationship with ALS clinical presentation and disease progression.
At the end of this project, we will identify the imaging inflammatory signature of ALS as a potential tool for early diagnosis and quick read out of drug efficacy in people with ALS.
Stan Appel, M.D., Methodist Neurological Institute, $2,270,585
Pilot Trial of the Safety and Tolerability of Expanded Autologous Regulatory T Cells Administered by Intravenous Infusion in People with ALS
The purpose of this study is to isolate T regulatory (Treg) cells from the blood using leukapheresis and expand Treg cells in the laboratory in twelve people with ALS. Leukapheresis is a laboratory procedure in which white blood cells are separated from a sample of blood. Once separated, the remainder of the blood is returned to the circulation. The subject’s Treg cells will be grown (manufactured) in a specialized GMP laboratory facility, tested and purified. The subject’s own expanded Treg cells will then be injected into the skin with or without the addition of IL-2 (Interleukin-2).This study may lead to Treg cell therapy for symptom management or potential slowing of disease progression in ALS and related disorders.
Two Clinical Phase II Trials, $3,000,000
As discussed in the July 2014 press release, The ALS Association announced $3 million of funding of two Phase II clinical trials as part of ALS ACT. These include the following:
Robert Miller, M.D., California Pacific Medical Center, San Francisco, CA
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS)
In collaboration with NEALS and Neuraltus Pharmaceuticals, Inc., Robert Miller, M.D. of the California Pacific Medical Center will lead a placebo-controlled, six-month treatment study to confirm a signal observed in a previous study of NP001, an immune system regulator. Inflammation is thought to be a contributing factor to ALS disease progression and existing NP001 data suggest that it may have an effect on inflammation in the immune system.
Michael Weiss, M.D., of the University of Washington Medical Center in Seattle
Effects of mexiletine on cortical hyperexcitability in amyotrophic lateral sclerosis
In collaboration with NEALS, Michael Weiss, M.D., of the University of Washington Medical Center in Seattle, will lead an eight-week study comparing the effect of several dosages of mexiletine on markers of hyperexcitability. A prior study showed that mexiletine was safe to use in ALS.
Per the October 2, 2014 announcement, The ALS Association is funding the New York Genome Center’s Consortium for Genomics of Neurodegenerative Disease (NYGC CGND). The New York Genome Center is a state-of-the-art consortium, possesses the capability of generating and analyzing thousands of ALS patient DNA sequences. NYGC brings a wealth of knowledge combining the latest technology with esteemed Institutional Founding Members, Associate Members, a Founding Technology Member and internal faculty with joint appointments at the member institutions. The mission of the NYGC-CGND is to harness state-of-the-art genetic, genomic and bioinformatics tools to gain insights into motor neuron disease mechanisms and to use this knowledge to identify new diagnostic and therapeutic approaches to these devastating diseases.
As discussed in the October 2, 2014 announcement, The Neuro Collaborative will combine the efforts of three leading California laboratories focused on ALS: The Svendsen lab at Cedars-Sinai in Los Angeles, the Cleveland lab at the University of California San Diego, and the Finkbeiner lab at the Gladstone Institutes, which is affiliated with UCSF.
The project is made possible by the unprecedented outpouring of support from the Ice Bucket Challenge. The Neuro Collaborative is one of four major new initiatives by The Association as a direct result of that support. The goal of the Neuro Collaborative is to discover and develop potential new therapies for ALS, which can be delivered to pharmaceutical companies for further development in clinical trials. Early development of potential therapeutics is a major bottleneck in ALS therapy development and represents a significant opportunity for accelerating new treatments.
As discussed in the October 2, 2014 announcement, The ALS Association has committed $1 million to Project MinE, an international effort to sequence the genomes of at least 15,000 people with ALS. The funding will be used to bring this effort to the United States, under the direction of researchers at University of Massachusetts Medical School in Worcester, Mass., and Emory University in Atlanta, Ga.
Melinda Kavanaugh, Ph.D., Assistant Professor of Social Welfare at the University of Wisconsin in Milwaukee, $50,000
On May 12, 2015 The ALS Association announced funding of a study of young people who care for someone with ALS to better understand the needs of youth caregivers and to design support services to address those needs. While the proportion of families with a teen or child caring for a person with ALS is unknown, it is clear that many ALS families include youth who may assume caregiver roles. The new study will collect data on ALS families nationwide and conduct interviews with youth caregivers to better understand their experiences.
The ALS Association and the American Academy of Neurology (AAN) announced that Hristelina Ilieva, M.D., Ph.D., of the Department of Neurology at the Johns Hopkins School of Medicine, Baltimore, Md., is this year’s recipient for the Clinical Research Training Fellowship. The purpose of the award is to recruit talented and promising young clinicians who propose innovative clinical research and to foster their development to make significant contributions to ALS clinical research.
On June 3, The ALS Association announced the awarding of $1.2 million of new funding to advance the discovery of biomarkers that correlate with important clinical and pathological aspects of ALS disease progression. This funding will be paired with a $539,000 match donation intended for research. The awards will fund three projects, each of which focuses on the discovery of biomarkers in ALS:
Jeremey Shefner, M.D., Ph.D., Robert Bowser, Ph.D., and Shafeeq Lahda, M.D., of Barrow Neurological Institute in Phoenix, Arizona, $539,841
Expansion of NEALS Biorepository at Barrow Neurological Institute, Phoenix Ariz. and Deep Phenotyping
This project will carry out a longitudinal collection of blood and Cerebrospinal fluid (CSF) from 150 people with ALS over the course of their disease. At the same time, detailed clinical measurements will be made of respiratory function, cognitive function, muscle strength, and other aspects of the disease. The fluids and clinical data will be stored in the NEALS biorepository and be made available for biomarker discovery research. The NEALS biorepository is a major site for storage, curation, and research on ALS biosamples. This project will be led by Jeremey Shefner, M.D., Ph.D., Robert Bowser, Ph.D., and Shafeeq Lahda, M.D., of Barrow Neurological Institute in Phoenix, Arizona. This research project is also supported by a generous matching gift from Mary Lou and Ira Fulton.
Andreas Jeromin, Ph.D., and Robert Bowser, Ph.D., of Iron Horse Diagnostics of Scottsdale, Ariz., co-funded by the National Institutes of Health, $200,000
Biomarker Validation Study
This study will attempt to provide a validation of a proteomic signature of ALS in the CSF of 300 people with the disease. The validation study will build on previous results showing that the ratio provides 92 percent sensitivity and 94 percent specificity for presence of ALS. Iron Horse will further validate these tests and perform both a prospective clinical study and assay qualification within a commercially certified (CLIA) laboratory to commercialize the diagnostic tests. Validation of the biomarker would allow further development and, ultimately, the first commercially available clinical test for presence of ALS.
National Institute of Health Rare Diseases Clinical Research Consortium, the Clinical Research in ALS and Related Disorders for Therapeutic Development Consortium (CReATe), $460,000
Biosample Collection for CReATe
This collection will support the growth and expansion of a biorepository for a newly funded National Institute of Health Rare Diseases Clinical Research Consortium, the Clinical Research in ALS and Related Disorders for Therapeutic Development Consortium. CReATe will bring together biochemists, geneticists, clinicians, Pharma, and partner groups involved in patient education and advocacy including The ALS Association, Muscular Dystrophy Association, ALS Recovery Fund, Association for Frontotemporal Degeneration, Spastic Paraplegia Foundation, PatientsLikeMe, and the National ALS Registry. The successful completion of the CReATe Consortium objectives will lay the necessary foundation for future trials in genetically homogeneous patient populations (including, for example, people with C9orf72 repeat expansions), thereby advancing science towards development of effective therapies for patients afflicted with these devastating degenerative disorders. As part of this initiative The ALS Association will support the enhancement of a repository of biosamples collected longitudinally with deep phenotyping of approximately 700 people with ALS. This effort, led by Michael Benatar, M.D., Ph.D., of the University of Miami, will combine detailed clinical data with biosample analysis to search for biomarkers that correlate with clinical characteristics, including patterns of disease spread and the rate of disease progression. Funding by The ALS Association will allow more extensive samples to be collected, stored, and shared with the ALS research community.
In July 2015, The ALS Association announced $1,500,000 in funding to Cytokinetics, Inc. to support the collection of clinical data and plasma samples to advance the discovery of biomarkers in ALS in VITALITY-ALS, a Phase 3 clinical trial of tirasemtiv in patients with ALS. For the first time, this unique collaboration between Cytokinetics, The ALS Association, and the Barrow Neurological Institute will enable plasma samples collected from patients enrolled in a Phase 3 clinical trial to be added to The Northeastern ALS Consortium (NEALS) Repository, a resource for the academic research community to identify biomarkers that may help to assess disease progression and underlying disease mechanisms in ALS.
In July 2015, The ALS Association announced its support of 58 new research grants totaling $11,621,638 million to find treatments and a cure for ALS. These awards include investigator-initiated grants, drug development contracts, Milton Safenowitz Postdoctoral Fellowships and support of the NEALS/TREAT ALS™ Clinical Trials Network. Descriptions and dollar amounts for each grant can be found here.
July 20, 2016
Partnership with ALS Finding a Cure as a part of ALS ACT for total of $2.96 million
Dr. Joshua Cohen, Amylyx Pharmaceuticals, Inc.: $734,350 for AMX0035 clinical trial. More information here.
Dr. Merit Cudkowicz, University of Massachusetts Medical School: 1,663,811. More information here.
Dr. Jeremy Shefner, St. Joseph’s Hospital and Medical Center: $958,010. More information here.
August 4, 2016
Partnership with ALS Finding a Cure as part of ALS ACT for total $3.6 million
Dr. Alex Sherman, Massachusetts General Hospital: $1,679,091 for NeuroBANK. More information here.
Bradley Foerster, M.D., Ph.D., University of Michigan in Ann Arbor: $294,017 to use multi-modal advanced imaging to capture the temporal phases of neuroinflammation in ALS. More information here.
Jeffrey Macklis, Ph.D., Harvard University: $300,000 to study potential abnormalities of corticospinal-specific growth cone proteomes, RNA and precise circuit wiring in ALS mice. More information here.
Jada Lewis, Ph.D., University of Florida: $300,000 to study new mouse models to dissect out the function of the ALS-associated protein Matrin. More information here.
Brian Black, Ph.D., University of California San Francisco: $300,000 to study the role of Zfp106 in RNA metabolism and ALS. More information here.
Mervyn Monteiro, Ph.D., the University of Maryland: $300,000 to perform gene profiling to determine the initiator mechanisms involved in disease in a UBQLN2 mouse model of ALS-FTD. More information here.
Jeffrey Rothstein, M.D., Ph.D., Johns Hopkins University: $300,000 to study how the C9orf72 nucleotide repeat expansion disrupts nucleocytoplasmic transport. More information here.
Thomas Maniatis, Ph.D., Columbia University: $300,000 to perform single-cell studies of ALS disease progression. More information here.
Wilfried Rossoll, Ph.D., Emory University in Atlanta: $300,000 to study molecular mechanisms of PABPN1-mediated suppression of TDP-43 toxicity. More information here.
Gene Yeo, Ph.D., University of California San Diego: $300,000 to study stress granule components in models of ALS. More information here.
Thomas Lloyd, M.D., Ph.D., Johns Hopkins University: $300,000 to study mechanisms of cytoplasmic protein aggregation and neurodegeneration in Drosophila (fly) models of C9orf72 ALS. More information here.
Peter Todd, M.D., Ph.D., University of Michigan: $25,000 to study the involvement of the C-terminal fragment in C9ALS/FTD RAN-translated dipeptide repeat toxicity. More information here.
Carlos A. Castañeda, Ph.D., Syracuse University: $50,000 to study the effects of ubiquilin-2 ALS mutations on structure, dynamics and interactions with other ALS-associated proteins. More information here.
Marco Peviani, Ph.D., Dana Farber Cancer Institute: $50,000 to develop microglia-targeted MRI/PET traceable nanovectors as an innovative therapeutic platform for investigating and shaping microglia reactivity to improve ALS therapy. More information here.
Sandra Almeida, Ph.D., University of Massachusetts Medical School: $50,000 to study methods for reducing repeat toxicity as a therapeutic approach in C9orf72 ALS/FTD. More information here.
Mai ElMallah, Ph.D., University of Massachusetts Medical School: $50,000 to develop gene therapy for upper airway dysfunction and respiratory insufficiency in an ALS mouse model. More information here.
Kausiki Datta, Ph.D., University of Florida: $50,000 to develop a high-throughput screening assay to identify small molecules that decrease transcription of the C9orf72 expansion. More information here.
Chunlai Wu, Ph.D., Louisiana State University Health Sciences Center: $50,000 to study enhancing the activity of a gene called Mask as a therapeutic approach for treating ALS due to mutations in the FUS gene. More information here.
Nadine Bakkar, Ph.D., St. Joseph's Hospital and Medical Center: $50,000 to study disruption of the integrity of the barrier between blood and cerebrospinal fluid in ALS. More information here.
Nicolas Fawzi, Ph.D., Brown University: $50,000 to study disruption of TDP-43 granule assembly by ALS mutations.
November 4, 2016
Partnership with ALS Finding a Cure and ALS ONE
Dr. Steven Perrin, ALS Therapy Development Institute: $650,000 to therapies targeting the inflammatory pathway. More information here.
Dr. Nazem Atassi, Massachusetts General Hospital: $675,000 to build a regional clinical trial network.
Dr. Robert Brown, University of Massachusetts Medical School: $675,000 to develop strategies to silence the production of toxic RNA and proteins from the mutant gene C9orf72.
Dr. Jiou Wang, Johns Hopkins University: $400,000 to project “Targeting proteotoxicity as the common denominator in ALS.”
Dr. Andrea Malaspina, Queen Mary University of London: $60,000 to project “Going Dry: empowering neurofilament-based biomarkers studies for disease monitoring in amyotrophic lateral sclerosis.”
Dr. Albert Ascherio, Harvard University: $275,000 to project “Nutrition and Disease Prevention: Examining polyunsaturated fats and risk of ALS.”
December 2, 2016
Partnership with ALS Finding a Cure and NEALS for $1,000,000 total
Dr. Ettore Beghi, IRCCS Mario Negri Institute for Pharmacological Research in Italy: $500,000 to project “The effects of RNS60 on ALS biomarkers.”
December 7, 2016
Partnership with Prize4Life
Dr. John Landers, University of Massachusetts Medical School: $568,896
Dr. Jonathan Glass, Emory University: $102,489
February 9, 2017 Press Release
Dr. Thomas Lloyd, Johns Hopkins University: Preclinical development of KPT-350 for C9-ALS: $500,000 over 2 years. More information here.
Dr. Richard Keenan, Optikira LLC: Validating inhibition of IRE1alpha kinase/RNase as a therapeutic approach to ALS: $498,000 over 2 years. More information here.
March 2, 2017
Vicente Valenzuela, Ph.D., University of Chile: $100,000. More information on his project here.
Bruno Miguel da Cruz Godinho, Ph.D., University of Massachusetts Medical School: $100,000. More information on his project here.
Sergey Stavisky, Ph.D., Stanford University in Stanford: $100,000. More information on his project here.
Tiffany Todd, Ph.D., Mayo Clinic in Jacksonville: $100,000. More information on her project here.
Jeanne McKeon, Ph.D., University of Massachusetts Medical School: $100,000. More information on her project here.
Amanda Gleixner, Ph.D., University of Pittsburgh: $100,000. More information on her project here.
March 13, 2017
In partnership with ALS Finding a Cure
Dr. Timothy Miller and team, Washington University in St. Louis: Developing a TDP-43 PET Tracer: $1,000,000 total prize
March 15, 2017
In partnership with the Essey family
Dr. John Ravits, University of California San Diego
March 16, 2017
In partnership with the American Academy of Neurology (AAN)
Dr. Sabrina Paganoni, University of Massachusetts Medical School: Clinician Scientist Development Award: $130,000: A phase 2 study of urate elevation in ALS
Dr. Nicholas Olney, University of California San Francisco: Clinical Research Training Fellowship: $240,000: Cervical spine imaging and CSF neurofilament light chain as biomarkers in patients with ALS
April 21, 2017
In partnership with the Motor Neurone Disease Association and PatientsLikeMe
Dr. Ammar Al-Chalabi, King’s College, London: $250,000 total grant
Dr. Don Cleveland, University of California San Diego: $1,000,000
Dr. Clive Svendsen, Cedars-Sinai: $1,000,000 to ALS on a Chip project
Dr. Carlos Castañeda, Syracuse University, $300,000, Molecular basis and effects of Ubiquilin-2 phase separation on association with ALS-linked proteins
Dr. Magdalini Polymenidou, University of Zurich, $300,000, Understanding the role of dynamic polymerization of TDP-43 in health and disease
Dr. Philip Wong, Johns Hopkins University, $300,000, TDP-43 splicing repression as a therapeutic target for ALS
Dr. Shuying Sun, Johns Hopkins University, $300,000, RAN translation of hexanucleotide repeats in C9ORF72-ALS/FTD
Dr. Marka Van Blitterswijk, Mayo Clinic Jacksonville, $250,000, Identification of novel biomarkers for C9ORF72-linked diseases, combining a targeted approach with an unbiased screen
Dr. Claudia Fallini, University of Massachusetts Medical School, $300,000, Dissecting the link between cytoskeletal disruption and mRNA processing in ALS
Dr. J. Paul Taylor, St. Jude Children’s Research Hospital, $300,000, How disturbance in stress granule dynamics is converted into TDP-43 pathology
Dr. Mart Saarma, University of Helsinki, $300,000, CDNF and CDNF variants - a novel therapy for ALS
Dr. Antonella Favit-VanPelt, Thera Neuropharma, $300,000, Selection of a novel target clinical candidate for the treatment of ALS
Dr. Randall Tibbetts, University of Wisconsin, $300,000, Drosophila models of ubiquilin-associated ALS
Dr. Jeffrey Agar, Northeastern University, $300,000, Tethering cysteine pairs with cyclic disulfides: a method for stabilizing fALS SOD1 variants
Dr. Chunlai Wu, Louisiana State University Health Sciences Center - New Orleans, $300,000, Enhancing Mask/ANKHD1 activity as a therapeutic approach for treating ALS
Dr. Elijah Stommel, Dartmouth College, $300,000, Investigating aerosolized cyanobacteria in Amyotrophic Lateral Sclerosis
Dr. Krista Spiller, University of Pennsylvania, $50,000, Uncovering ALS-related changes in motor circuits and their functional consequences on subsequent disease progression in rNLS8 mice
Dr. Gabriella Viero, Institute of Biophysics CNR, $50,000, Tag-free axonal translatome of mouse models of ALS/FTD to reveal defects in axonal mRNA transport and association to axonal polysomes
Dr. Qiang Zhu, Ludwig Institute for Cancer Research, $50,000, Determining whether gain of toxicity from ALS/FTD-linked hexanucleotide repeat expansion synergizes with reduced C9ORF72 function to drive age-dependent ALS/FTD
Dr. Jacob Ayers, University of Florida, $50,000, Developing a mouse model to study the cell-type specific effects on ALS disease spread
Dr. Sandrine Da Cruz, Ludwig Institute for Cancer Research, $50,000, Identifying molecular targets to enhance muscle innervation in Amyotrophic Lateral Sclerosis
Dr. Megan McCain, University of Southern California, $50,000, Engineering robust and functional human neuromuscular junctions in a dish for ALS disease modeling and drug screening
Dr. Mariana Pehar, Medical University of South Carolina, $50,000, RAGE inhibition as a therapeutic approach in ALS models
Dr. Philip Smaldino, Ball State University, $50,000, Enzymatic regulation of toxic G-quadruplex structures in ALS cells by G4 resolvase 1
Dr. Meredith Jackrel, Washington University, $50,000, Countering TDP-43, FUS, and dipeptide repeat protein toxicity with engineered Hsp104 variants
Dr. Timothy Lu, Massachusetts Institute of Technology, $50,000, Ameliorating TDP-43-associated pathogenesis with global transcriptional perturbations
Dr. Anthony Giampetruzzi, University of Massachusetts Medical School, $100,000, Identifying therapeutics for ALS using ALS-linked mutant Profilin-1
Dr. Maria Purice, St. Jude Children’s Research Hospital, $100,000, Linking TDP-43 pathology with stress granule dynamics
Dr. Yue Li, Scripps Florida, $100,000, Development of RNA-templated small molecules to treat C9ALS/FTD
Dr. Nibha Mishra, Massachusetts General Hospital, $100,000, Identifying determinants of FUS nucleocytoplasmic localization by CRISPR/Cas9 genetic screen in ALS patient cells
Dr. Meredith Corley, University of California San Diego, $100,000, Accurate RNA structural studies of transcripts targeted by RNA binding protein hnRNP A2/B1
Dr. Stephen Goutman, University of Michigan, $200,000, Utility of 3D printed masks for improving compliance and efficacy of non-invasive ventilation in subjects with amyotrophic lateral sclerosis: A pilot feasibility study
Dr. Orla Hardiman, Trinity College Dublin, $200,000, A randomised controlled study of psychological intervention in ALS to address the significant and complex mental health issues facing caregivers
Dr. David Walk, University of Minnesota, $134,392, A pilot study of lung volume recruitment combined with expiratory muscle strength training to facilitate ventilatory and bulbar function in ALS
Dr. Raymond Roos, The University of Chicago, $200,000, Combating ER stress in G85R ALS mice
Dr. Nicolas Maragakis, Johns Hopkins University, $200,000, A GLP-1 analog for the treatment of ALS
Dr. Antonius Bunt, Izumi Biosciences LLC, $100,000, Complement DoD grant W81XWH-16-1-0072 for PK enhancement of cART in HERV-K + ALS-FTD patients to reverse neuroinflammation, multi drug resistance and improve outcomes
Dr. John Landers, University of Massachusetts Medical School, $200,000, Investigating pridopidine, a Sigma-1 receptor activator, as a novel therapeutic treatment for ALS
Dr. Timothy Miller, Washington University, $77,750, Pathological analysis of selective autophagy in sporadic and familial ALS
Dr. Wen Hwa Lee, University of Oxford, $200,000, Generation and validation of open access recombinant monoclonal antibodies for reproducible ALS research
Dr. Eliahu Heldman, Lauren Science LLC, $75,000, Treatment of ALS by non-invasive, targeted delivery of GDNF to motor neurons using novel V-SmartTM nanovesicles (LAUR-301)
Dr. John Ravits, Regents of the University of California, $47,250, Pathological analysis of selective autophagy in sporadic and familial ALS
Dr. Chad Heatwole, University of Rochester, $225,241, Development of a clinically relevant outcome measure for ALS therapeutic trials
Dr. Gilles Guillemin, Macquarie University, 60,000, New directions for early diagnosis of MND: a large-scale longitudinal analysis of multiple biomarkers to find diagnostic and progostic "fingerprints"
Dr. Steven Finkbeiner, The J. David Gladstone Institutes, $1,000,000, ALSA-Neuro Collaborative identification and validation of therapeutic targets and developments of therapeutics for ALS
Dr. John Landers, University of Massachusetts Medical School, $841,271, Project MinE US-Whole genome sequencing of a large cohort of sporadic ALS patients
Dr. Don Cleveland, Ludwig Institute for Cancer Research, $60,000, Trans-cellular transmission of misfolded TDP-43 and ALS progression
Dr. Adele McCormick, University of Westminster, $327,000, Trans-cellular transmission of misfolded TDP-43 and ALS progression
Dr. Markus Otto, University of Ulm, $200,000, Neurofilament Assay